Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

vituximab toward later-stage clinical trials. Planning for this exciting next phase for our bavituximab oncology program has already begun."

Mr. King added, "This past year we also made significant advancements in our bavituximab and broader anti-PS anti-viral program, receiving high-profile international validation through the publication of data in the highly respected scientific journal Nature Medicine, which confirmed the anti-viral potential of bavituximab and our other anti-PS antibodies. We were also successful in completing contract negotiations with the DTRA, allowing us to expand the evaluation of our anti-PS antibodies as potential broad spectrum agents for the treatment or prevention of viral hemorrhagic fever virus infections. This contract directly or indirectly supports our bavituximab and other anti-PS technology programs and represents another significant validation for the anti-PS technology platform."

Mr. King continued, "Our Cotara clinical program continues to advance with patient enrollment nearing completion in our dose confirmation and dosimetry study in patients with recurrent glioblastoma (GBM), and enrollment exceeds the halfway mark in our Phase II trial in relapsed GBM patients. We recently presented dosimetry study data at the Society of Nuclear Medicine 2009 Annual Meeting, further confirming that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs, reinforcing its potential as a possible new treatment for GBM."

At April 30, 2009, Peregrine had $10 million in cash and cash equivalents, compared to $15.1 million in cash and cash equivalents at April 30, 2008. After the close of the 2009 fiscal year, Peregrine raised approximately $6.9 million in gross proceeds from the sale of common stock from its existing shelf registration. The stock was sold in an "At the Market" offering as defined in Rule 415
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... September 15, 2014 Ondine Biomedical ... Loebel, its President and Chief Technology Officer, will ... Photodynamic Therapy (PDT) and Photodiagnosis in Clinical Practice. ... Brixen/Bressanone (Italy) from October 14-18, 2014 alongside the ... on October 13-14th, is an annual conference at ...
(Date:9/15/2014)... Octo Consulting Group, a leading provider ... federal government, today announced it is opening two ... to better serve existing and future federal government ... to the strong growth momentum of the company’s ... consulting, agile software development, data visualization, and data ...
(Date:9/15/2014)... approximately one out of every 40 individuals in the United ... muscular atrophy (SMA), a neurodegenerative disease that causes muscles to ... have made a recent breakthrough with the development of a ... of the disease. In April, a patent was filed for ... lab is using to fight SMA is to ,repress the ...
(Date:9/15/2014)... Ohio (PRWEB) September 15, 2014 In ... math and medicine often act conjointly to quantify, define ... industry has become an integral part of medical care. ... regularly reports the studies conducted by the non-profit Institute ... have consistently demonstrated that math can be much more ...
(Date:9/15/2014)... Dennis Thompson HealthDay Reporter ... severe respiratory virus believed to have sickened hundreds of ... spread to the Northeast, health officials report. The ... more than a dozen cases of infection with Enterovirus ... asthma. And on Saturday, the Connecticut Department of ...
Breaking Medicine News(10 mins):Health News:Ondine Presenting at the 2014 International Symposium on Photodynamic Therapy and Photodiagnosis 2Health News:Octo Consulting Group Announces it is Opening Two New Offices in Alexandria, Virginia and Atlanta, Georgia to Better Serve Existing and Future Federal Government Clients 2Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3
... and LONDON , July 16 Since January 2009, ... awards for its work in patient education and design. In ... four 2009 Communicator Awards from the International Academy ... the company was further notified of six more awards (two ...
... , , , HOUSTON, ... first and largest provider of outsourced implantable medical device management solutions to ... chief executive officer. The appointment follows the company,s tenth quarter of ... Partners , a leading private equity firm focused exclusively on healthcare. ...
... July 16 "We,ll quit before we practice government medicine" will be ... on July 17. , , The Association ... co-sponsor the protests at the local home office of each Congressman and ... run medicine. , , Taxpayers ...
... N.Y., July 16 In an order filed on July 13, ... District of Florida appointed as Lead Counsel to the Plaintiffs, Steering ... Esq., a partner in Parker Waichman Alonso LLP, and Scott Wm. ... , Co-Lead Counsel,s responsibility is to represent ...
... , , DENVER, July 16 ... named the best respiratory hospital in the nation by U.S. News ... "We are gratified that board-certified pulmonologists around the country continue to recognize ... care," said Michael Salem, MD, President and CEO of National Jewish Health. ...
... COLUMBUS, Ohio, July 16 Mettler-Toledo International Inc. (NYSE: MTD ... Company,s second-quarter results on Thursday, July 23, 2009 at 5:00 p.m. Eastern ... www.mt.com/investors on the Company,s website. A replay of the webcast ... , METTLER TOLEDO is a leading global supplier of precision ...
Cached Medicine News:Health News:MediciGlobal Achieves Record Number of Awards 2Health News:Access MediQuip Names Tim Hargarten Chief Executive Officer 2Health News:Access MediQuip Names Tim Hargarten Chief Executive Officer 3Health News:ANDRES F. ALONSO, ESQ., a Partner in the Law Firm of PARKER WAICHMAN ALONSO LLP, Was Appointed Co-Lead Counsel to the Plaintiffs' Steering Committee in the Denture Cream Products Liability Litigation, MDL 2051 2Health News:National Jewish Health Named Top Respiratory Hospital for 12th Consecutive Year 2
(Date:9/15/2014)...  Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) ... criteria for the NASDAQ Global Select Market and effective ... the NYSE MKT. The company will continue to trade ... NASDAQ Global Select Market, a segment of the NASDAQ ... any exchange in the world, requiring that strict financial, ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Pathology Market by Slide Scanners, Analytics, Delivery Modes & ... Trends to 2018" report to their offering. ... pathology market into different products and applications. Scanners accounted ... market, followed by analytics. The analytics market is expected ...
(Date:9/15/2014)... N.J. , Sept. 15, 2014   Hudson ... , in cooperation with Johns Hopkins University , ... a commercially viable high-throughput screening (HTS) system for ... Logo - http://photos.prnewswire.com/prnh/20140912/145910 This ... (ARQiv) system, will bring high-throughput screening technology into ...
Breaking Medicine Technology:Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3Global Digital Pathology Market by Slide Scanners, Analytics, Delivery Modes & by Whole Slide Image Storage - Forecasts & Trends to 2018 2Global Digital Pathology Market by Slide Scanners, Analytics, Delivery Modes & by Whole Slide Image Storage - Forecasts & Trends to 2018 3Hudson Robotics and Johns Hopkins Receive NIH Grant for Zebrafish HTS System 2
Inquire...
... of electronic refractors. The TRS replaces your standard ... a keypad that is small enough to sit in ... Chart Projector. The TRS is programmable so that at ... moved for you, taking you to your next refraction ...
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
... Ideal for satellite clinics or for ... value, the Debut stand is an ... construction and molded composite body offer ... counterbalanced slit-lamp arm--one of two arms ...
Medicine Products: